|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103.43 USD | -2.73% |
|
-3.03% | +4.72% |
| Jan. 13 | TD Cowen Adjusts Price Target on Incyte to $128 From $101, Maintains Buy Rating | MT |
| Jan. 12 | Incyte Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 08:15 AM |
Company Valuation: Incyte Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 19,048 | 16,213 | 17,869 | 14,072 | 13,306 | 20,306 | 20,306 | - |
| Change | - | -14.88% | 10.21% | -21.25% | -5.44% | 52.6% | 0% | - |
| Enterprise Value (EV) 1 | 17,535 | 13,865 | 14,630 | 10,416 | 11,148 | 16,311 | 14,748 | 12,967 |
| Change | - | -20.93% | 5.52% | -28.81% | 7.03% | 46.31% | -9.59% | -12.08% |
| P/E ratio | -64x | 17.2x | 52.8x | 23.7x | 460x | 16.7x | 15.5x | 13.8x |
| PBR | 7.26x | 4.32x | 4.09x | 2.71x | 3.88x | 3.52x | 2.72x | 2.15x |
| PEG | - | -0x | -0.8x | 0.3x | -4.9x | 0x | 2.06x | 1.1x |
| Capitalization / Revenue | 7.14x | 5.43x | 5.26x | 3.81x | 3.14x | 4.08x | 3.67x | 3.35x |
| EV / Revenue | 6.58x | 4.64x | 4.31x | 2.82x | 2.63x | 3.28x | 2.67x | 2.14x |
| EV / EBITDA | -82.8x | 21.5x | 24.5x | 14.8x | 22.2x | 9.85x | 7.7x | 6.42x |
| EV / EBIT | -66.5x | 23.7x | 25.2x | 16.8x | 26.9x | 9.99x | 7.72x | 5.82x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.36 | 4.27 | 1.52 | 2.65 | 0.15 | 6.194 | 6.66 | 7.47 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,667 | 2,986 | 3,395 | 3,696 | 4,241 | 4,975 | 5,530 | 6,061 |
| EBITDA 1 | -211.9 | 643.6 | 597.7 | 703.2 | 503.1 | 1,657 | 1,914 | 2,021 |
| EBIT 1 | -263.7 | 585.8 | 579.4 | 620.5 | 413.9 | 1,633 | 1,910 | 2,227 |
| Net income 1 | -295.7 | 948.6 | 340.7 | 597.6 | 32.62 | 1,241 | 1,329 | 1,546 |
| Net Debt 1 | -1,513 | -2,348 | -3,239 | -3,656 | -2,158 | -3,995 | -5,558 | -7,339 |
| Reference price 2 | 86.98 | 73.40 | 80.32 | 62.79 | 69.07 | 103.43 | 103.43 | 103.43 |
| Nbr of stocks (in thousands) | 218,996 | 220,891 | 222,475 | 224,109 | 192,650 | 196,323 | 196,323 | - |
| Announcement Date | 2/9/21 | 2/8/22 | 2/7/23 | 2/13/24 | 2/10/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.17x | 3.39x | 10.19x | -.--% | 20.87B | |
| 18.8x | 5.09x | 12.9x | 0.48% | 78.8B | |
| 56.01x | 14.81x | 31.76x | -.--% | 58.65B | |
| 42.26x | 6.56x | 21.08x | 0.56% | 55.89B | |
| 22.45x | 4.1x | 11.92x | 2.62% | 56.73B | |
| 17.89x | 2.95x | 9.28x | -.--% | 27.23B | |
| 81.98x | 9.73x | 87.73x | -.--% | 19.74B | |
| 350.52x | 106.34x | 172.79x | - | 17.33B | |
| -22.45x | 32.26x | -32.95x | -.--% | 14.81B | |
| Average | 64.96x | 20.58x | 36.08x | 0.46% | 38.9B | |
| Weighted average by Cap. | 47.45x | 12.95x | 26.96x | 0.66% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- INCY Stock
- Valuation Incyte Corporation
Select your edition
All financial news and data tailored to specific country editions
